A team of Ropes & Gray attorneys is advising Johnson & Johnson in its acquisition of Aragon Pharmaceuticals, Inc., including rights to its second generation prostate cancer drug ARN-509, for $650 million in cash upfront and up to $350 million in contingent payments. The deal enhances Johnson & Johnson’s leadership in prostate cancer drug development, which is one of its main areas of focus, and provides the potential for novel approaches to treat prostate cancer patients.
The Ropes & Gray team was led by life sciences partner Michael Sexton, private equity transactions associates Michael Gilbert and Charlie Boer and corporate associate Erin Turban.
Articles in The Deal Pipeline and Law360 reported on this deal.
